A Prospective Multicentric Cohort Study To Evaluate The Tolerance Of Colchicine In Patients Of Crystal Arthritis

Dr. Belinda Philip; Dr. (Col.) Vishal Marwaha; Dr. Sobha Subramaniam; Dr. Aneesh Joseph; Dr. Vijith Vijay; Dr. Sandeep Surendran; Dr. Mithun CB; Dr. Arun Tiwari; Dr. Princy Louis Palatty; Dr. George Mathews John; Dr. (Lt. Col.) Priyank Yadav; Dr. Saroj Kumar; Dr. Rajesh Kanumuri; Dr. Abhishek Kumar; Dr. Anuj Singhal

Volume : X, Issue : VII, July - 2020

A Prospective Multicentric Cohort Study To Evaluate The Tolerance Of Colchicine In Patients Of Crystal Arthritis

Dr. Belinda Philip, Dr. Col. Vishal Marwaha, Dr. Sobha Subramaniam, Dr. Aneesh Joseph, Dr. Vijith Vijay, Dr. Sandeep Surendran, Dr. Mithun Cb, Dr. Arun Tiwari, Dr. Princy Louis Palatty, Dr. George Mathews John, Dr. Lt. Col. Priyank Yadav, Dr. Saroj Kumar, Dr. Rajesh Kanumuri, Dr. Abhishek Kumar, Dr. Anuj Singhal

Abstract :

Introduction: Colchicine is approved therapy for management of acute crystal arthritis and secondary prevention of arthritis episodes. There is paucity of studies from India to establish tolerance colchicine for long term. Hence, this study was carried to study the tolerance of colchicine over 6 months or more. Materials and Methods: This study was conducted from 1 January 2016 to 31 December 2018 and in 5 centres across India. In this study, 174 patients were recruited who were on tablet colchicine 0.5mg twice daily for at least 6 months. Patients were observed for development of adverse effects and intolerance. Results: Out of the 174 recruited patients, the adverse effects were noted in 7.4% (n=13). Most common adverse effect was diarrhoea followed by abdominal pain, nausea, vomiting, constipation, and elevated creatine kinase levels. Conclusion: Our study shows that tablet colchicine is a well tolerated drug in the management of crystal arthritis for long term prophylaxsis